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Background
Comorbid post-traumatic stress disorder (PTSD) is associated
with poorer outcomes of other disorders, but is treatable.
Aims
To estimate the frequency of clinically undetected PTSD in
secondary care.
Method
A systematic review of studies that screened for PTSD and
reported on PTSD documentation in clinical records. Frequency
of undetected PTSD was estimated, and reasons for hetero-
geneity explored.
Results
The median proportion of participants with undetected PTSD (29
studies) was 28.6% (interquartile range 18.2–38.6%). There was
substantial heterogeneity, with studies conducted in the USA
and those with the highest proportions of in-patients and
patients with psychotic disorder reporting higher frequencies of
undetected PTSD.
Conclusions
Undetected PTSD is common in secondary care, even if the true
value is at the lower limit of the estimates reported here. Trials
examining the impact of routine screening for PTSD are required
to determine whether such programmes should be standard
procedure for all mental health services.
Declaration of interest
None.
Copyright and usage
©The Royal College of Psychiatrists 2018. This is an OpenAccess
article, distributed under the terms of the Creative Commons
Attribution licence (http://creativecommons.org/licenses/by/
4.0/), which permits unrestricted re-use, distribution, and
reproduction in any medium, provided the original work is
properly cited.
Identification of comorbid post-traumatic stress disorder (PTSD)
in patients with other serious mental illness is of substantial
importance given that this is associated with poorer clinical out-
comes of these disorders,1–4 and that PTSD is a treatable disorder.5
Some studies suggest that a large proportion of patients in second-
ary-care mental health services with other (non-PTSD) primary
diagnoses meet criteria for PTSD on screening, and that there is
usually no record of PTSD in the patient’s clinical records.6–9 If
these estimates of undetected PTSD are accurate this raises a
serious concern that PTSD is not adequately identified through
routine clinical care pathways. Other studies, however, report
much lower frequencies of undetected PTSD.10–12 Reasons for
variation in estimates of PTSD across studies could include differ-
ences in the characteristics of the people in the study (such as
gender, primary diagnosis) or of the study methodology (such as
measurement or selection bias). An accurate estimate of the fre-
quency of undetected PTSD in secondary care, and an under-
standing of factors associated with variation in frequency is
required to determine if, and how, services should respond. In
this study, we systematically review the literature to determine
whether undetected PTSD is present at a prevalence that would
reflect substantial clinical importance within secondary-care
mental health services. For the purpose of this study we define
‘substantial clinical importance’ as presence of undetected PTSD
in 10% or more of patients in secondary care, an arbitrary value
but one that we believe most service providers would agree
merits clinical concern. Furthermore, we also aim to determine
the extent to which variation in reported estimates might be
because of sample characteristics or methodological biases. To
our knowledge there have not been any previous systematic
reviews addressing these aims.
Method
Our protocol (online supplement DS1 available at https://doi.org/
10.1192/bjp.2017.8; not pre-registered) followed Meta-analysis Of
Observational Studies in Epidemiology (MOOSE) guidelines13
and a PRISMA checklist was completed (online supplement DS2).
Literature search
We (S.D.) searched the following databases from 1980 to 22 August
2016: Embase, Medline, PILOTS and PsycINFO using relevant
keywords and subject headings (online supplement DS3). We (H.C.,
H.M., A.P. and S.Z.) hand searched reference lists of included
studies to identify further relevant papers. We restricted the search
to published, peer-reviewed studies, but not by study design. Only
English-language studies were included.
Selection criteria
Our inclusion criteria were: (a) participants in secondary care (i.e.
specialist mental health services) with a mental illness diagnosis
according to DSM or ICD criteria; (b) screened for PTSD using a
measure based on DSM or ICD criteria; (c) used medical records
to obtain participants’ clinical diagnoses of PTSD; (d) reported pro-
portion of sample with PTSD on screening, and with PTSD in
medical records; and (e) reported data for individuals aged 16 and
over. Studies where samples were selected on the basis of (a)
having a diagnosis of PTSD, (b) having a trauma history, or (c)
being referred to a trauma service were excluded.
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Study selection and data extraction
We examined all titles and abstracts (S.Z., H.C. and A.P.) and
obtained full texts of potentially relevant papers. Working inde-
pendently and in duplicate, we (S.Z., C.L., H.R., H.C., A.P. and
H.M.) read the papers to determine if they met inclusion criteria
using eligibility record forms (online supplement DS4). We resolved
disagreements by consensus, and extracted data independently and
in duplicate.
Quality assessment
The likely internal validity for each study was assessed (S.Z., C.L.
and H.R.) based on key selected components of a risk of bias tool
for prevalence studies,14 adapted for this review. We focused par-
ticularly on sampling strategy, response rates, and masking of
screening assessment and clinical records review as the likeliest
sources of bias in estimating frequency of undetected PTSD. For
examination of heterogeneity, studies were also categorised into
low, medium, and high risk of selection bias (online Table DS1).
Data synthesis
The proportion of PTSD that was detected (recorded) in clinical
notes was estimated as: n with PTSD on record/n with PTSD on
screening. The proportion with undetected PTSD was estimated
as: (n with PTSD on screening – n with PTSD on record)/sample
n. We grouped studies together and pooled data in a meta-analysis,
although such summary estimates are only useful where studies are
adequately homogenous. Studies were pooled using a random-
effects model (usingmetaprop in Stata version 14). Presence of pub-
lication bias was investigated by viewing funnel plots and using
Egger’s test.15 We assessed heterogeneity using the I2 statistic.16
We investigated sources of heterogeneity by meta-regression
using the metareg command. We hypothesised that frequency of
PTSD on screening might be higher for veterans (because of poten-
tially greater exposure to traumas, and increased recognition by
clinicians), patients diagnosed with a psychotic disorder (as the
hierarchical approach to diagnosis and the phenotypic overlap
between re-living experiences and hallucinations could lead to
reduced identification of PTSD compared with other diagnoses),
in-patients (as potentially indexing more severe illness), studies
using self-report PTSD questionnaires (as lower specificity than
interviews) and in studies with a greater likelihood of selection
bias, and that frequency might vary by country of study (because
of different rates of PTSD in different populations). We also exam-
ined, as secondary hypotheses, variation in relation to age (as greater
cumulative exposure to trauma with age), gender (as PTSD is more
common in women) and year of publication (as services studied in
recent publications might be more aware of comorbid PTSD).
We also examined pooled estimates for specific diagnostic cat-
egories: (a) psychotic disorders, (b) affective disorders (depressive
disorders and bipolar disorder), (c) substance use disorders, (d)
anxiety and adjustment disorders, (e) eating disorders, and (f) per-
sonality disorders. As relatively few studies included only partici-
pants with one primary diagnosis or presented results separately
for diagnostic groups, we also repeated these analyses including
studies where >50% of the sample had the same diagnosis.
Results
Search results
The literature search yielded 7581 references. After reading titles
and abstracts, the full articles of 223 papers were assessed for
eligibility, and 194 of these were excluded (PRISMA flow
diagram, Fig. 1).
Included studies
We included 29 studies (6412 individuals) that had data to allow us
to estimate the extent of undetected PTSD in a secondary-care
mental health setting (online Table DS2). Of these, 15 were based
in the USA,7–11,17–26 3 in each of Australia,27–29 the UK6,30,31 and
the Netherlands,32–34 2 in Germany,12,35 and 1 each in South
Africa,36 Spain37 and Turkey.38 Three studies were in military
veteran populations7,17,18 and 26 were in non-veterans, 1 within
an incarcerated population.23 Most studies (n = 16) included indivi-
duals with a variety of mental health disorders, whereas the rest
ascertained individuals with specific disorders (six with substance
use disorders,7,17,22,30,31,33 four with psychotic disorders,6,18,32,34
two with mood or anxiety disorders28,36 and one with eating disor-
ders35). The mean age of participants (28 studies) was 38.8 years
(range 26.5 to 51.9 years).
Prevalence of PTSD
The median prevalence of PTSD on screening was 33.3% (inter-
quartile range (IQR) 23.4–40.0%), with evidence of substantial
heterogeneity across studies (pooled mean 31%, 95% CI 26–36%,
I2 = 93.1%) (online Fig. DS1). When we examined the prevalence
of PTSD on screening within specific disorder categories the hetero-
geneity was substantially lower for studies with a primary diagnosis
of a substance use disorder, but not for other diagnostic groups
(online Fig. DS2). The mean prevalence of PTSD on screening in
samples of participants with a substance use disorder was 36%
(95% CI 33–40%, study n = 6, 793 individuals, I2 = 0%), with a
psychotic disorder was 31% (95% CI 21–41%, study n = 6, 2994
individuals, I2 = 89.1%), with an affective disorder was 39% (95%
CI 19–62%, study n = 3, 155 individuals, I2 = 87.4%) and with a
mixture of disorders was 30% (95% CI 22–39%, study n = 16,
2303 individuals, I2 = 94.5%).
The median prevalence of PTSD diagnoses in clinical records
was 2.3% (IQR 1.1–4.5%), with evidence of substantial heterogen-
eity (mean 3%, 95% CI 2–4%, I2 = 85.3%). Of those with PTSD
on screening, median level of detection (i.e. recorded in notes)
was 11.5% (IQR 2.8–19.4%), with substantial heterogeneity across
studies (mean 10%, 95% CI 6–16%, I2 = 86.6%).
Undetected PTSD
The median proportion of participants within each study that had
undetected PTSD was 28.6% (IQR 18.2–38.6%), with evidence of
substantial heterogeneity across studies (mean 27%, 95% CI 22–
32%, I2 = 93.3%) (Fig. 2). There was no evidence of publication
bias arising from an absence of small studies with lower proportions
of undetected PTSD (Egger test (29 studies), P = 0.743).
The mean prevalence of undetected PTSD in participants with
psychotic disorders was 28% (95%CI 19–37%, study n = 6, 2994 indi-
viduals, I2 = 86.3%), with substance use disorders was 27% (95% CI
21–34%, study n = 6, 793 individuals, I2 = 71.1%), with affective dis-
orders was 34% (95% CI 14–57%, study n = 3, 155 individuals, I2 =
88.5%), and for samples with a mixture of disorders was 27% (95%
CI 19–35%, study n = 16, 2303 individuals, I2 = 94.4%) (Fig. 3).
Results were similar when we included studies where more than
half of participants had the same diagnosis (online Fig. DS3). In a
stratified analysis there was no evidence that undetected PTSD
was less common when restricting studies to those using a
structured interview for screening for PTSD (median propor-
tion 26.3%, IQR = 20.3–38.6%) compared with those using a
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self-report questionnaire (median proportion 28.8%, IQR = 15.5–
40.6%).
Exploring heterogeneity
Given the strong evidence of heterogeneity, the overall estimates of
undetected PTSD are not particularly informative, and we therefore
explored potential sources of heterogeneity (Table 1 and online
Table DS3).
PTSD on screening
Meta-regression showed strong evidence that levels of PTSD on
screening varied across country of origin (P = 0.005, residual I2 =
19.6%), with estimates being higher in studies from the USA
(USA v. rest: difference 13%, 95% CI 4–22%, P = 0.007). There
was very weak evidence that PTSD on screening was higher in
studies with higher proportions of older participants (P = 0.078)
and men (P = 0.071), but little evidence that other variables
explained heterogeneity.
Clinical detection of PTSD
There was some evidence that PTSD, if present on screening, was
less likely to have been detected in samples with a higher proportion
of patients with a psychotic disorder (P = 0.024), and more likely to
have been detected in samples of veterans (P = 0.053) and studies
that used interviews to screen for PTSD (P = 0.068). There was
little evidence that variation in detection of PTSD was associated
with the other variables examined.
Undetected PTSD
There was some evidence from meta-regression that levels of
undetected PTSD were higher in studies from the USA (P =
0.050) and in studies on in-patients (P = 0.072), but little evidence
that levels were higher in studies with proportions of patients
with a psychotic disorder (P = 0.156). However, in a multivariable
model including the primary explanatory variables, there was
strong evidence that undetected PTSD was higher in studies from
the USA (P = 0.001) and in samples with greater proportions of
patients with a psychotic disorder (P = 0.006).
Quality assessment
A total of 14 of the 29 studies described either random sampling or
sampling of consecutive admissions or patient contacts (online
Table DS3). Of these 14 studies, 9 reported response rates, 5 of
which included data from 75% or more of eligible patients.
Masking of researchers to PTSD histories in clinical records was
reported for 3 of the 16 studies25 that relied on research interviewers
SEARCH PROCESS 1:
Biomedical database searches
(see online supplement DS1 for details)
MEDLINE = 7001
Embase = 1595
PsycINFO = 3473
PILOTS = 1537
SEARCH PROCESS 2:
Additional resources
Reference lists = 5
Others = 0
SCREENING: Numer of records
screened after de-duplication
n = 7581
Records
excluded:
n = 7358
ELIGIBILITY: Full-text articles 
assessed
n = 223
INCLUDED STUDIES: Included in
quantitative analysis
n = 29
Records
excluded:
n = 194 
No clinical records
(104)
Not secondary care
(28)
No PTSD screen
(10)
Abstract only (13)
Review/editorial
(14)
Age <16 (3)
Non-English (13)
Other (9)
Fig. 1. PRISMA flow diagram.
PTSD, post-traumatic stress disorder.
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to determine the presence of PTSD on screening, whereas 13 studies
used self-report screening measures. Masking of researchers to PTSD
screening results when searching the clinical records for PTSD diag-
noses was reported for 2 of the 29 studies,10,25 and 1 study excluded
participants with PTSD in their clinical records at study entry.36
Estimates of PTSD on screening were lower for studies with the
lowest risk of bias in a stratified analysis, although confidence inter-
vals overlapped substantially (lowest risk 24%, 95% CI 12–40%;
intermediate risk 31%, 95% CI 22–41%; highest risk 35%, 95% CI
28–42%). A similar pattern was observed for estimates of
undetected PTSD (lowest risk 21%, 95% CI 9–36%; intermediate
risk 29%, 95% CI 19–39%; highest risk 28%, 95% CI 22–33%).
Discussion
In this systematic review we found the frequency of PTSD on
screening was very high in samples of patients ascertained
through secondary-care services. Although there was substantial
heterogeneity in estimates, precluding any useful interpretation of
a summary meta-analytic estimate, the IQR across studies ranged
from 23 to 40%, indicating that a substantial proportion of patients
in secondary-care mental health services met criteria for PTSD in
most studies to date.
The frequency of PTSD on screening was high, whereas the
frequency with which PTSD was documented in the clinical
records was low. Our results indicate that in the majority of cases,
mental health clinicians fail to recognise PTSD in their patients.
Furthermore, given how common PTSD was on screening, the
failure of clinical recognition of this disorder was one that poten-
tially affected a substantial proportion of all patients under the
care of specialist mental health services.
Possible explanations
This interpretation of our results depends on a number of key
assumptions. First, we are assuming that a diagnosis of PTSD
would have been noted in the clinical records had mental health
staff identified this as being present. Although it is possible clini-
cians may have been aware of a PTSD diagnosis but deemed it as
irrelevant to the patient’s current presentation and not worthy of
recording, this seems unlikely. A second, and perhaps more critical
assumption, is that the screening tools used to identify PTSD in
these studies were valid and did not substantially overestimate the
presence of PTSD. A total of 13 studies used self-report question-
naire measures, and all measures used have been validated, with
good specificity against the Clinician-Administered PTSD Scale
(CAPS) that is considered to be the gold-standard for assessment
of PTSD (0.86 for the PTSD checklist (PCL);39 0.93 for the
Trauma Screening Questionnaire (TSQ);40 0.71 for the PTSD
symptom scale – self report version (PSS-SR);41 0.71 for Self-
Report Inventory for PTSD (SRIP)42). More relevant, however, is
the positive predictive values (PPVs) of these instruments. The
PCL, as used by some studies in this review, had a PPV of 0.8
(cut-off score 50) in a sample where 45% of participants had
PTSD39 and a PPV of 0.7 in another study with a PTSD prevalence
of 39%.43 Similarly the PPV for the TSQ (6+ items cut-off) was 0.86
in a study with a PTSD prevalence of 34%,40 for the SRIP (cut-off 52)
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was 0.71 with a PTSD prevalence of 47%,44 and for the PSS-SR was
0.64 with a PTSD prevalence of 43%.45
The true proportion of PTSD in these samples if screened with a
gold-standard assessment might therefore be slightly lower than
that estimated in these studies, although it is unlikely to be substan-
tially lower. Consistent with this, although only 2.1% of the sample
in one study had a diagnosis of PTSD in their clinical records,33 only
a further 2.7% had a record of ‘possible PTSD’, making minimal dif-
ference to the estimates for undetected PTSD (34.8% compared with
32.2% respectively). Only three studies in our review used the CAPS,
however, many studies used other diagnostic interviews that are also
likely to be robust measures of PTSD. Furthermore, there was little
evidence from the meta-regression that the type of PTSD assess-
ment tool was associated with explaining heterogeneity in the fre-
quency of PTSD on screening.
The third, and final, assumption is that the studies are not biased
in a way that leads to substantial overestimates of undetected PTSD.
We assessed the quality of these studies, focusing particularly on the
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strategy for sampling and response rates as being the most likely
sources of selection bias. Studies that did not sample all consecutive
admissions, or a random sample of patients, may have recruited
individuals with an increased likelihood of having experienced a
traumatic event, and consequently of having PTSD; for example,
patients with a known trauma history may have been selected for
recruitment by researchers/clinicians, or may have been more
likely to participate. Such scenarios could lead to overestimates in
the prevalence of PTSD on screening, and hence undetected
PTSD in our review. Most studies were susceptible to such selection
bias, and PTSD on screening and undetected PTSD were lower in
studies rated with lowest risk of bias. However, there was little evi-
dence from the meta-regression that selection bias risk was asso-
ciated with heterogeneity in prevalence of undetected PTSD.
Although selection bias might have led to overestimates of
PTSD on screening, there are also a number of reasons why preva-
lence of undetected PTSD may have been underestimated. Absence
of masking of researchers to clinical diagnosis when conducting
screening interviews, and to screening outcome when retrieving
clinical records, introduces the possibility of information bias that
would most likely lead to underestimates of undetected PTSD.
Furthermore, in two studies underestimates of undetected PTSD
may have been particularly likely. One study excluded patients
with high scores on the Brief Psychiatric Rating Scale,37 thus poten-
tially excluding individuals with greater likelihood of PTSD given
the association between comorbid PTSD and illness severity. In
the other, screening results were entered into the clinical notes,22
potentially influencing discharge diagnoses.
Heterogeneity
The strongest characteristic associated with prevalence of PTSD on
screening and of undetected PTSD was country, with studies from
the USA having substantially higher levels of PTSD than other
countries. This is consistent with population-based studies of
PTSD that report lifetime prevalence of 8% in the USA46 compared
with 1.9% in Europe.47 Explanations for differences across countries
are almost certainly complex and likely to involve cultural dynamics
and historical context, as well as variation in exposure to interper-
sonal violence and other sources of trauma.48,49 PTSD was also
less likely to be detected in patients with psychotic disorders. One
explanation for this is that symptoms of PTSD can be interpreted
as psychotic, particularly if severe; for example, re-living experi-
ences, especially during dissociative states, can be classed as halluci-
nations, and altered beliefs about safety and trust characteristic of
severe PTSD can be experienced with delusional intensity.
Strengths and limitations
We had a comprehensive search strategy in terms of the search
terms and databases searched to ensure we identified relevant
studies, however, we excluded studies that were not published in
the English language, and this may have led to some studies being
missed. Furthermore, although we took a rigorous approach to
address heterogeneity in our results the number of studies in
these analyses meant that power may have been limited to identify
factors that had smaller effects on frequency of undetected PTSD.
Although the degree of heterogeneity precluded us from deriving
a meta-analytical estimate for undetected PTSD, nevertheless
estimates from 22 of the 29 studies were consistent with at least
10% of patients having undetected PTSD (our a priori definition
of clinical importance) as judged by the bounds of the confidence
intervals.
Finally, the ability of a systematic review to inform evidence
depends upon the quality of the included studies. A number of
studies had potential for selection bias, although limiting studies to
those with low risk of bias did not alter the conclusions of our find-
ings. Furthermore, although the use of self-report questionnaires as
screening instruments may be viewed as an important limitation of
many of the included studies in that they might overestimate the fre-
quency of undetected PTSD, there was no evidence that the frequency
of undetected PTSD was any lower when restricting our analyses to
studies that used only structured interviews for screening.
Implications
If, as suggested by our IQR, 18 to 39% of patients in secondary-care
mental health services have undetected PTSD, this has important
implications for clinical services. Increased training of mental
health staff in identifying symptoms of PTSD, and perhaps particu-
larly in distinguishing re-living experiences from psychotic symp-
toms, seems warranted.
Presence of comorbid PTSD is associated with poorer clinical
outcomes for a number of disorders. More importantly, it is possible
that for some patients, the disorder being treated by clinicians
(for example depression, agoraphobia, obsessional–compulsive dis-
order, addictions, psychosis) is secondary to PTSD; failure to recog-
nise and treat the underlying PTSD can lead to failure in recovery
from these secondary disorders. This is avoidable, as PTSD is a
treatable disorder.5
Concerns about high levels of undetected PTSD have been
voiced for approximately two decades,8,22,25 yet many healthcare
providers do not appear to have taken adequate steps to address
this problem, as evidenced by the more recent publications in our
review. There is clearly a need for more robust methodology to
more accurately determine the extent to which PTSD goes
undetected within clinical services, and to determine the likely
cost to individuals, service providers and society that might serve
as drivers to motivate change. However, even if the true value of
undetected PTSD is at the lower limit of the IQR reported here,
there is a clear need to trial a PTSD screening programme to
examine its feasibility and impact on clinical outcomes. If shown
to improve patient outcomes and be cost-effective, such screening
Table 1 Meta-regression of primary variables explaining variation in frequency of undetected post-traumatic stress disorder (PTSD)
Unadjusted Adjustedb
Variablea β (95% CI) P β (95% CI) P
Bias risk (low) −0.02 (–0.09 to 0.05) 0.545 −0.02 (–0.08 to 0.04) 0.473
Country 0.09 (–0.01 to 0.19) 0.050 0.16 (0.07 to 0.25) 0.001
In-patients 0.05 (–0.01 to 0.11) 0.072 0.04 (–0.00 to 0.09) 0.063
Psychosis 1.05 (–0.43 to 2.53) 0.156 1.44 (0.45 to 2.42) 0.006
PTSD tool −0.01 (–0.11 to 0.10) 0.917 0.00 (–0.09 to 0.08) 0.979
Veterans 0.01 (–0.16 to 0.18) 0.886 −0.09 (–0.22 to 0.05) 0.202
a. Bias risk (low) – coded as non-low (0), medium (1), low (2); country – coded as USA (1) v. rest (0); in-patients – coded as out-patients only (0), mixed (1), in-patients only (2); psychosis – per
10% increase in sample with a psychotic disorder; PTSD tool – coded as interview (0) v. questionnaire (1); veterans – coded as veterans (1) v. non-veterans (0).
b. Adjusted for other variables in the table (residual I2 = 5.6%)
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programmes should become a standard part of secondary-care
mental health services in the future.
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psychiatry in
pictures
Juana la Loca
Rafael Euba
‘Her words are so moving, it is very hard for the Marquise and me to resist them. Her supplications stir in me the
deepest compassion’. She is Queen Joanna of Castile, begging to be released. The person so moved by the
unfortunate queen is the Marquis of Denia, her guardian, or perhaps her jailer, depending on the point of view.
‘Juana la Loca’ (1479–1555) was confined in Tordesillas because of her mental illness. It is believed that she may
have had either schizophrenia or a psychotic melancholia, popularly attributed to the loss of her husband, Philip
‘The Handsome’. The image of the heart-broken queen – who, incidentally, appears in her portraits to be better
looking than her ‘handsome’ husband – wandering the Castilian steppe with her entourage and Philip’s coffin, and
later imprisoned, has inspired countless paintings, films and novels, most of them containing the words ‘love’ and
‘madness’ in their titles. These stories, always sympathetic to Joanna, also assume that she was a de facto political
prisoner of the males in her family, her father King Ferdinand and her son Charles I, who allegedly usurped her
throne by locking her away. The contemporary descriptions of her behaviour however, are certainly consistent
with a severe and chronic psychotic illness.
She was kept in Tordesillas against her will until her death after nearly 50 years, while her father Ferdinand ‘the
Catholic’ and her son Emperor Charles ruled her kingdoms on her behalf. Joanna was allowed to keep Catalina of
Austria, her youngest daughter, with her until the girl eventually left Tordesillas to become Queen of Portugal.
Joanna’s psychosis, and more importantly her incarceration, had a profound impact on Spain’s history.
One of the most famous representations of Juana on canvas is by Francisco Pradilla, currently held by Museo
Nacional del Prado in Madrid.
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